These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31120285)

  • 21. Cannabis, cannabidiol, and epilepsy--from receptors to clinical response.
    Szaflarski JP; Bebin EM
    Epilepsy Behav; 2014 Dec; 41():277-82. PubMed ID: 25282526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract.
    Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM
    Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic Use of Δ9-THC and Cannabidiol: Evaluation of a New Extraction Procedure for the Preparation of Cannabis-based Olive Oil.
    Morini L; Porro G; Liso M; Groppi A
    Curr Pharm Biotechnol; 2017; 18(10):828-833. PubMed ID: 29189144
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular and Cellular Mechanisms of Action of Cannabidiol.
    Martinez Naya N; Kelly J; Corna G; Golino M; Abbate A; Toldo S
    Molecules; 2023 Aug; 28(16):. PubMed ID: 37630232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of cannabidiol on delta-9-tetrahydrocannabinol effects.
    Dalton WS; Martz R; Lemberger L; Rodda BE; Forney RB
    Clin Pharmacol Ther; 1976 Mar; 19(3):300-9. PubMed ID: 770048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cannabidiol fails to reverse hypothermia or locomotor suppression induced by Δ(9) -tetrahydrocannabinol in Sprague-Dawley rats.
    Taffe MA; Creehan KM; Vandewater SA
    Br J Pharmacol; 2015 Apr; 172(7):1783-91. PubMed ID: 25425111
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain.
    Bornheim LM; Kim KY; Li J; Perotti BY; Benet LZ
    Drug Metab Dispos; 1995 Aug; 23(8):825-31. PubMed ID: 7493549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delta9-THC as a discriminative cue in pigeons: effects of delta8-THC, CBD, and CBN.
    Järbe TU; Henriksson BG; Ohlin GC
    Arch Int Pharmacodyn Ther; 1977 Jul; 228(1):68-72. PubMed ID: 921403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Δ
    Silveira MM; Adams WK; Morena M; Hill MN; Winstanley CA
    J Psychiatry Neurosci; 2017 Mar; 42(2):131-138. PubMed ID: 28245177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion of cannabidiol (CBD) to Δ9-tetrahydrocannabinol (Δ9-THC) during protein precipitations prior to plasma samples analysis by chromatography - Troubles with reliable CBD quantitation when acidic precipitation agents are applied.
    Dybowski MP; Dawidowicz AL; Typek R; Rombel M
    Talanta; 2020 Dec; 220():121390. PubMed ID: 32928411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between cannabidiol and psychosis: A review.
    Silva TB; Balbino CQ; Weiber AF
    Ann Clin Psychiatry; 2015 May; 27(2):134-41. PubMed ID: 25954940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology of Medical Cannabis.
    Amin MR; Ali DW
    Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents.
    Fasinu PS; Phillips S; ElSohly MA; Walker LA
    Pharmacotherapy; 2016 Jul; 36(7):781-96. PubMed ID: 27285147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diminished gray matter in the hippocampus of cannabis users: possible protective effects of cannabidiol.
    Demirakca T; Sartorius A; Ende G; Meyer N; Welzel H; Skopp G; Mann K; Hermann D
    Drug Alcohol Depend; 2011 Apr; 114(2-3):242-5. PubMed ID: 21050680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
    Pertwee RG
    Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.
    Englund A; Morrison PD; Nottage J; Hague D; Kane F; Bonaccorso S; Stone JM; Reichenberg A; Brenneisen R; Holt D; Feilding A; Walker L; Murray RM; Kapur S
    J Psychopharmacol; 2013 Jan; 27(1):19-27. PubMed ID: 23042808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and initial psychometric properties of the Cannabidiol Outcome Expectancies Questionnaire (CBD-OEQ).
    Walukevich-Dienst K; Morris PE; Tucker RP; Copeland AL; Buckner JD
    Psychol Assess; 2022 Jul; 34(7):643-659. PubMed ID: 35298216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cannabidiol and substance use disorder: Dream or reality.
    Karimi-Haghighi S; Razavi Y; Iezzi D; Scheyer AF; Manzoni O; Haghparast A
    Neuropharmacology; 2022 Apr; 207():108948. PubMed ID: 35032495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cannabidiol as a candidate pharmacotherapy for sleep disturbance in alcohol use disorder.
    Gendy MNS; Frey BN; Van Ameringen M; Kuhathasan N; MacKillop J
    Alcohol Alcohol; 2023 Jul; 58(4):337-345. PubMed ID: 37139966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cannabidiol reduces ethanol consumption, motivation and relapse in mice.
    Viudez-Martínez A; García-Gutiérrez MS; Navarrón CM; Morales-Calero MI; Navarrete F; Torres-Suárez AI; Manzanares J
    Addict Biol; 2018 Jan; 23(1):154-164. PubMed ID: 28194850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.